Antares Pharma Inc  

(Public, NASDAQ:ATRS)   Watch this stock  
Find more results for ATRS
4.06
+0.08 (2.01%)
May 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.99 - 4.07
52 week 2.60 - 5.58
Open 4.00
Vol / Avg. 1.30M/1.00M
Mkt cap 512.27M
P/E     -
Div/yield     -
EPS -0.13
Shares 126.18M
Beta 0.75
Inst. own 37%
Aug 5, 2013
Q2 2013 Antares Pharma, Inc. Earnings Release Add to calendar
May 22, 2013
Antares Pharma, Inc. Annual Shareholder Meeting - 10:00AM EDT - Add to calendar
May 16, 2013
Antares Pharma, Inc. at Bank of America Merrill Lynch Health Care Conference
May 8, 2013
Q1 2013 Antares Pharma, Inc. Earnings Conference Call
May 6, 2013
Q1 2013 Antares Pharma, Inc. Earnings Release
Mar 13, 2013
Q4 2012 Antares Pharma, Inc. Earnings Conference Call
Mar 11, 2013
Q4 2012 Antares Pharma, Inc. Earnings Release
Mar 6, 2013
Antares Pharma, Inc. at Cowen Health Care Conference
Feb 27, 2013
Antares Pharma, Inc. at RBC Capital Markets' Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -75.27% -50.62%
Operating margin -75.16% -50.73%
EBITD margin - -49.70%
Return on average assets -14.67% -16.62%
Return on average equity -16.07% -19.42%
Employees 42 -
Carbon Disclosure Rating - -

Address

Suite 300, 100 Princeton South
EWING, NJ 08628
United States - Map
+1-609-3593020 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products. The Company�s subcutaneous and intramuscular injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, it has licensed its reusable needle-free injection device for use with human growth hormone (hGH) to Teva, Ferring Pharmaceuticals BV (Ferring) and JCR Pharmaceuticals Co., Ltd. (JCR), with Teva and Ferring being its two primary customers. The Company has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices. In the gel-based area, it received Food and Drug Administration (FDA) approval in December 2011 for its oxybutynin gel 3% product, Anturol.

Officers and directors

Leonard S. Jacob M.D., Ph.D. Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Paul K. Wotton Ph.D. President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Robert F. Apple CPA Chief Financial Officer, Executive Vice President, President - Parenteral Products Division
Age: 45
Bio & Compensation  - Reuters
Kaushik J. Dave Ph.D. Executive Vice President - Product Development
Age: 50
Bio & Compensation  - Reuters
Peter Sadowski Ph.D. Senior Vice President, Chief Technology Officer
Age: 64
Bio & Compensation  - Reuters
Thomas J. Garrity Independent Director
Age: 63
Bio & Compensation  - Reuters
Jacques Gonella Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Anton Gueth Independent Director
Age: 55
Bio & Compensation  - Reuters
Eamonn P. Hobbs Independent Director
Age: 53
Bio & Compensation  - Reuters
Rajesh C. Shrotriya M.D Independent Director
Age: 68
Bio & Compensation  - Reuters